Zydus Lifesciences Ltd on Tuesday, March 4, said it will develop a combination vaccine against shigellosis and typhoid for infants and children.The company said this vaccine combination is being developed for the first time in the world. The project is expected to get underway in March 2025 and is being supported by the Gates Foundation, it added.
The pharma company will collaborate with a partner for research and co-development of the combination vaccine using Zydus’ WHO pre-qualified typhoid conjugate vaccine and the shigella vaccine from its partner.
“By collaborating with key partners and leveraging our research and development capabilities to provide novel solutions, we can bridge unmet needs through high-quality, and affordable vaccines that can create a sustainable impact in global public health,” Sharvil Patel, the managing director of Zydus Life said.The TCV-Shigella combination vaccine aims to protect children below five years against shigellosis, a diarrhoeal disease caused by the shigella bacteria and typhoid fever caused by salmonella bacteria in areas where both the diseases are endemic, the company said.
The pharma company will collaborate with a partner for research and co-development of the combination vaccine using Zydus’ WHO pre-qualified typhoid conjugate vaccine and the shigella vaccine from its partner.
“By collaborating with key partners and leveraging our research and development capabilities to provide novel solutions, we can bridge unmet needs through high-quality, and affordable vaccines that can create a sustainable impact in global public health,” Sharvil Patel, the managing director of Zydus Life said.The TCV-Shigella combination vaccine aims to protect children below five years against shigellosis, a diarrhoeal disease caused by the shigella bacteria and typhoid fever caused by salmonella bacteria in areas where both the diseases are endemic, the company said.
“We are excited about supporting this initiative by Zydus, which would leverage India’s science and innovation expertise, and has the potential to contribute significantly to protecting children, not just in India, but also in other parts of the world,” M Hari Menon, the country director of Gates Foundation, said.
Zydus Life shares were trading flat at ₹870.55 apiece at 11.15 am on Tuesday, March 4. The stock has declined 10.63% in the past month.
Also Read: Here is why Defence stocks Bharat Dynamics, Cochin Shipyard, GRSE surging on Tuesday
